Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ZC3H12A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ZC3H12A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ZC3H12A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ZC3H12A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ZC3H12A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ZC3H12A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00506883 | Oral cavity | OSCC | regulation of defense response to virus | 42/7305 | 69/18723 | 1.92e-04 | 1.29e-03 | 42 |
GO:00517029 | Oral cavity | OSCC | biological process involved in interaction with symbiont | 54/7305 | 94/18723 | 2.20e-04 | 1.44e-03 | 54 |
GO:000715916 | Oral cavity | OSCC | leukocyte cell-cell adhesion | 178/7305 | 371/18723 | 2.44e-04 | 1.57e-03 | 178 |
GO:007121910 | Oral cavity | OSCC | cellular response to molecule of bacterial origin | 112/7305 | 221/18723 | 2.64e-04 | 1.69e-03 | 112 |
GO:00300983 | Oral cavity | OSCC | lymphocyte differentiation | 179/7305 | 374/18723 | 2.74e-04 | 1.74e-03 | 179 |
GO:190303715 | Oral cavity | OSCC | regulation of leukocyte cell-cell adhesion | 162/7305 | 336/18723 | 3.39e-04 | 2.08e-03 | 162 |
GO:000268310 | Oral cavity | OSCC | negative regulation of immune system process | 204/7305 | 434/18723 | 3.72e-04 | 2.27e-03 | 204 |
GO:00346612 | Oral cavity | OSCC | ncRNA catabolic process | 28/7305 | 43/18723 | 4.71e-04 | 2.79e-03 | 28 |
GO:19021059 | Oral cavity | OSCC | regulation of leukocyte differentiation | 136/7305 | 279/18723 | 5.53e-04 | 3.21e-03 | 136 |
GO:00302175 | Oral cavity | OSCC | T cell differentiation | 126/7305 | 257/18723 | 6.51e-04 | 3.66e-03 | 126 |
GO:00071629 | Oral cavity | OSCC | negative regulation of cell adhesion | 145/7305 | 303/18723 | 9.95e-04 | 5.18e-03 | 145 |
GO:00507774 | Oral cavity | OSCC | negative regulation of immune response | 97/7305 | 194/18723 | 1.16e-03 | 5.91e-03 | 97 |
GO:00985866 | Oral cavity | OSCC | cellular response to virus | 47/7305 | 84/18723 | 1.20e-03 | 6.06e-03 | 47 |
GO:00609666 | Oral cavity | OSCC | regulation of gene silencing by RNA | 32/7305 | 53/18723 | 1.32e-03 | 6.56e-03 | 32 |
GO:00609649 | Oral cavity | OSCC | regulation of gene silencing by miRNA | 30/7305 | 49/18723 | 1.35e-03 | 6.62e-03 | 30 |
GO:200037916 | Oral cavity | OSCC | positive regulation of reactive oxygen species metabolic process | 43/7305 | 76/18723 | 1.41e-03 | 6.84e-03 | 43 |
GO:00199154 | Oral cavity | OSCC | lipid storage | 48/7305 | 87/18723 | 1.60e-03 | 7.62e-03 | 48 |
GO:001063418 | Oral cavity | OSCC | positive regulation of epithelial cell migration | 88/7305 | 176/18723 | 1.91e-03 | 8.94e-03 | 88 |
GO:00447887 | Oral cavity | OSCC | modulation by host of viral process | 20/7305 | 30/18723 | 1.99e-03 | 9.23e-03 | 20 |
GO:00601478 | Oral cavity | OSCC | regulation of posttranscriptional gene silencing | 31/7305 | 52/18723 | 2.08e-03 | 9.59e-03 | 31 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZC3H12A | SNV | Missense_Mutation | novel | c.925N>C | p.Gly309Arg | p.G309R | Q5D1E8 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
ZC3H12A | SNV | Missense_Mutation | novel | c.698N>T | p.Ala233Val | p.A233V | Q5D1E8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A2FE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
ZC3H12A | SNV | Missense_Mutation | novel | c.754N>A | p.Glu252Lys | p.E252K | Q5D1E8 | protein_coding | deleterious(0.02) | probably_damaging(0.954) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
ZC3H12A | SNV | Missense_Mutation | | c.1711N>A | p.Ala571Thr | p.A571T | Q5D1E8 | protein_coding | tolerated(0.33) | benign(0.044) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZC3H12A | SNV | Missense_Mutation | | c.1792N>G | p.Ser598Gly | p.S598G | Q5D1E8 | protein_coding | deleterious_low_confidence(0.02) | benign(0) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
ZC3H12A | SNV | Missense_Mutation | | c.1684N>A | p.Gly562Ser | p.G562S | Q5D1E8 | protein_coding | deleterious(0.04) | benign(0.219) | TCGA-BH-A0E0-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
ZC3H12A | SNV | Missense_Mutation | | c.1457N>G | p.Ala486Gly | p.A486G | Q5D1E8 | protein_coding | tolerated(0.57) | benign(0.001) | TCGA-E9-A245-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ZC3H12A | SNV | Missense_Mutation | novel | c.574N>G | p.Pro192Ala | p.P192A | Q5D1E8 | protein_coding | tolerated(0.25) | probably_damaging(0.99) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
ZC3H12A | SNV | Missense_Mutation | novel | c.725C>T | p.Ser242Phe | p.S242F | Q5D1E8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZC3H12A | insertion | Nonsense_Mutation | novel | c.971_972insTTGCTAAGAGTCCCCTAGCATCTTCCTGATGGTCTTTCTGCCTT | p.Glu324AspfsTer3 | p.E324Dfs*3 | Q5D1E8 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |